[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adhd---combined-type\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adhd---combined-type":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,86,126,149,170,192,216],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100551865","phase-4-methylphenidate-in-kbg-syndrome-n-of-1-series-100551865",false,"NCT06465641","Methylphenidate in KBG Syndrome: N-of-1 Series","Effectiveness of Methylphenidate in Children and Adolescents With KBG Syndrome: An N-of-1 Series","KBGS_N_of_1","Inclusion Criteria:\n\n* Age 6-20 years\n* Molecularly confirmed diagnosis of KBG syndrome (pathogenic ANKRD11 variant or a chromosome 16q24 deletion including ANKRD11)\n* Attention deficit or ADHD-related symptoms or a formal ADHD diagnosis, with a significant impact on daily life\\*\n* Presence of a subject's caregiver or supervisor for proxy-reports\n\nExclusion Criteria:\n\n* Family history of acute cardiac death that warrants further cardiac investigation\n* Cardiovascular disease in medical history (severe hypertension, heart failure, arterial occlusive disease, potentially life-threatening arrythmias, angina pectoris, hemodynamically significant congenital heart defect, cardiomyopathy, myocardial infarction and channelopathy)\n* Current or previous presence of hyperthyroidism, glaucoma or pheochromocytoma\n* Use of (psychotropic\u002Fstimulant) drugs which interact with MPH\n* Schizophrenic or psychotic disorder in medical history\n* Unstable epilepsy (not controlled with medication)\n* History of frequent drug and\u002For alcohol abuse\n* Excessive alcohol\u002Fdrug use and\u002For intoxication with one or both during the study\n* Pregnant or lactating women\n* Inability to understand or speak Dutch","ALL","6 Years","20 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial\\] is to learn about the effect of methylphenidate in children and adolescents with KBG syndrome. The main question it aims to answer is:\n\n• What is the effectiveness of methylphenidate on attention deficit and ADHD-related symptoms in children and adolescents with KBG syndrome?\n\nParticipants will receive multiple blocks of treatment with methylphenidate and placebo and fill out various questionnaires.",[28,29],"Kbg Syndrome","ADHD - Combined Type","RECRUITING","2026-08-10",{"date":33,"type":34},"2026-08-11","ACTUAL",{"date":36,"type":34},"2024-11-13",{"date":38,"type":22},"2028-10-01",{"name":40,"class":41},"Radboud University Medical Center","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":42},"100650932","a-clinical-trial-evaluating-fecal-microbiota-transplantation-fmt-in-adolescents-with-adhd-100650932","NCT07756255","A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD","Feasibility, Safety and Tolerability of Fecal Microbiota Transplantation in an Adolescent Population With Attention Deficit Hyperactivity Disorder (ADHD)","FMT-ADHD-2026","Inclusion Criteria:\n\n1. Between 13-17 years of age with consent of a legal guardian: Participants should be at least 13 years old and not older than 17 years at the day of screening (V1).\n2. Have a primary diagnosis of ADHD as confirmed by the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).\n3. Be on a stable appropriate dose of an appropriate first-line pharmacological treatment for at least 8 weeks prior to the day of screening (V1).\n\n   a. First line pharmacotherapy treatment will be defined based on the CADDRA guidelines \\[63\\] and include the following\n\n   Amphetamine-based psychostimulants:\n\n   i. Mixed amphetamine salts (amphetamine and dextroamphetamine) ii. Lisdexamfetamine dimesylate\n\n   Methylphenidate-based psychostimulants:\n\n   i. Methylphenidate hydrochloride, Methylphenidate hydrochloride (extended release, multilayer release capsules) ii. Methylphenidate hydrochloride (extended release, OROS tablets) iii. Methylphenidate hydrochloride (controlled release, multi-layer beat capsules) iv. Methylphenidate hydrochloride (extended-release oral suspension)\n4. Have a score of ≥ 18 on the inattention subset (questions 1-9) and\u002For the hyperactivity\u002Fimpulsivity subset (questions 10-18) of the SNAP-IV 26-Item Parent Rating Scale on the day of screening (V1) and the baseline visit (V2).\n5. Able to communicate and complete study assessments in English.\n6. Able to comply with all protocol procedures.\n7. Consenting guardian\n\nExclusion Criteria:\n\n1. Participant meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria for the following conditions according to the MINI-KID:\n\n   1. Diagnosis of a Substance Use Disorder within the last 3 months prior to screening. \\*(Criteria should include Alcohol and Non-Alcohol substances except Cannabis)\n   2. Moderate or severe Substance Use Disorder for Cannabis use in the last 3 months\n   3. Currently active high suicidality. Eligibility of Participants who meet criteria for moderate suicidality is determined by clinical judgment of Principal Investigator.\n   4. Active Anorexia Nervosa or Bulimia Nervosa in the last 3 months.\n   5. Tic Disorders\n   6. Psychosis\n   7. Obsessive Compulsive Disorder\n   8. Bipolar Disorder\n   9. Conduct Disorder\n2. Participant has a score of ≥ 8 on the oppositional defiant subset of the SNAP-IV 26-Item Parent Rating Scale (questions 19-26) on the day of screening (V1).\n3. Intellectual or learning disability based on previous documented diagnosis or clinical judgment of Principal Investigator.\n4. Documented diagnosis of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) or Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS).\n5. Documented diagnosis of schizophrenia or schizoaffective disorder.\n6. Documented diagnosis of Autism Spectrum Disorder (ASD) or currently undergoing assessment for suspected ASD.\n7. Use of systemic antibiotics for medical purposes within the last 3 months prior to the day of screening (V1).\n8. Use of prebiotics or probiotics for medical purposes for more than 2 weeks within the last 3 months prior to the day of screening (V1).\n\n   a) Eligibility and required washout period of participants with use of over-the-counter prebiotics or probiotics will be determined by clinical judgment of Principal Investigator.\n9. Use of experimental drugs in the last 3 months prior to the day of screening (V1).\n10. Documented clinical diagnosis of inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, and\u002For celiac disease.\n11. Documented diagnosis of conditions causing immunosuppression and\u002For currently receiving immunosuppressive treatments.\n12. Documented clinical diagnosis of significant bleeding disorders.\n13. History of oropharyngeal dysphagia or other swallowing disorder, and\u002For self or study partner reported difficulty with taking oral capsules or pills.\n14. Breastfeeding, pregnant or seeking to get pregnant during the course of this study. Female participants of childbearing age should be using an acceptable method of birth control (implants, injectable, combined oral contraceptives, IUDs, barrier contraceptives, sexual abstinence, or a vasectomized partner) for the duration of their participation in the trial.\n15. Participants who are currently hospitalized or institutionalized.\n16. Reported allergy to Vancomycin or Nitazoxanide\n17. Hepatic dysfunction:\n\nA) Documented history or current diagnosis of an acute or chronic hepatic disease (e.g., cirrhosis, hepatitis, hepatic impairment) OR\n\nB) Abnormal - Liver Function Tests (LFTs): Screening laboratory results indicating clinically significant hepatic dysfunction:\n\n* Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥3 the Upper Normal Limit (UNL)\n* Total Bilirubin \\> 1.5 × ULN (except in cases of documented Gilbert's Syndrome) 19. Renal dysfunction: A) Diagnosed Renal Disease: Any documented medical history or current diagnosis of kidney disease, acute kidney injury, or other clinically significant renal impairment. OR B) Abnormal Renal Function Tests: Screening laboratory results indicating significant renal dysfunction. Creatinine \\> 1.5 × ULN\\*\n\n  * Potential participants presenting with mild, non-clinically significant laboratory abnormalities (e.g., AST\u002FALT between 1.0 and 3.0 × ULN, or isolated borderline creatinine variations confirmation of enrollment into the study will be dependent of the study physician.",true,"13 Years","18 Years",{"count":55,"type":22},64,[57],"PHASE2","The primary goals of this phase 2 clinical trial are to determine the feasibility, safety, and tolerability of oral Fecal Microbiota Transplantation (FMT) in adolescents (aged 13-17) with Attention-Deficit\u002FHyperactivity Disorder (ADHD).",[60,61,29],"ADHD","ADHD - Attention Deficit Disorder With Hyperactivity",[63,64,65,66,67,68,69,70,60,71,72,73,74,75,76],"microbiome","microbiota transplants","fecal microbiota transplantation","gut microbiome therapy","gut microbiome","gut microbiota","neurodevelopmental disorders","neurodevelopment","Attention Deficit Hyperactivity Disorder","gut brain axis","FMT","adolescent psychiatry","psychiatry","neuroscience","NOT_YET_RECRUITING","2026-08-05",{"date":31,"type":34},{"date":81,"type":22},"2026-08-31",{"date":83,"type":22},"2029-08-31",{"name":85,"class":41},"University of Calgary",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100522340","phase-2-sertraline-vs-placebo-in-the-treatment-of-anxiety-in-children-and-adolescents-with-neurodevelopmental-disorders-100522340","NCT06081348","Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","CALM","Inclusion Criteria:\n\n1. Outpatients 8-17 years of age, inclusive\n2. Females of child bearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.\n3. Meet Diagnostic and Statistical Manual of Mental Disorders - DSM-5 criteria for ASD, ADHD, Tic Disorders, or genetic diagnosis of Fragile X, tuberous sclerosis or 22q11 deletions.\n4. Meet DSM-5 criteria for one of the following anxiety disorders: Separation Anxiety Disorder, Social Anxiety Disorder, Agoraphobia, Generalized Anxiety Disorder, or Unspecified Anxiety Disorder, based on expert clinical interview, supported by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS; Kaufman et al., 2016). Other specified anxiety disorder is included to account for youth with impairing anxiety symptoms who may not meet criteria for one of the other anxiety disorders.\n5. Have a Clinician's Global Impression-Severity for anxiety (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill) (inter-rater reliability will be done prior to initiation of enrollment, using videotapes of interviews and vignettes)\n6. If already receiving interventions, must meet the following criteria:\n\n   1. If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening and will not electively modify ongoing medications for study duration\n   2. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions\n7. Ability to complete assessments in English\n\nExclusion Criteria:\n\n1. Receiving other SSRIs within four weeks of randomization (6 weeks for fluoxetine)\n2. Previous treatment with sertraline, at an adequate dose (at least 100mg for 6 weeks, or lower dose and duration if not well-tolerated), associated with no response or significant-to-the-participant side effects.\n3. Received more than 2 previous appropriate trials of SSRIs with no adequate response\n4. Pregnant females or sexually active females on inadequate contraception\n5. Serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger participant. In addition diabetic patients on medications for glycemic control will be excluded as sertraline may interfere with glycemic control.\n6. Hypersensitivity to sertraline or any components of its formulation\n7. On Monoamine Oxidase Inhibitors or pimozide (as per product monograph)\n8. On concomitant medications known to significantly increase QT interval where this would result in unacceptable risk per Investigator judgment.\n9. Known congenital QT prolongation\n10. HIV, hepatitis B or C, hemophilia, abnormal blood pressure, substance abuse, immunity disorder, major depressive episode or psychosis (as required by Health Canada)\n11. Unable to tolerate venipuncture\n12. Unable to swallow capsules\n13. Enrolled in another intervention study","8 Years","17 Years",{"count":97,"type":22},130,[57],"There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.",[101,102,103,104,105,106,107,60,108,109,110,111,29,112,113,114,115],"Neurodevelopmental Disorders","Autism","Autism Spectrum Disorder","Fragile X Syndrome","Tuberous Sclerosis","22Q11 Deletion Syndrome","22Q11 Deletion","Tic Disorders","Tourette Syndrome","Tourette Syndrome in Children","Tourette Syndrome in Adolescence","ADHD Predominantly Inattentive Type","ADHD, Predominantly Hyperactive - Impulsive","Anxiety","Anxiety Disorders","2026-07-24",{"date":118,"type":34},"2026-07-27",{"date":120,"type":34},"2024-09-16",{"date":122,"type":22},"2027-09",{"name":124,"class":41},"Holland Bloorview Kids Rehabilitation Hospital",7,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":133,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100641292","cardiovascular-abnormalities-in-children-with-attention-deficithyperactivity-disorder-100641292","NCT07655843","Cardiovascular Abnormalities in Children With Attention-deficit\u002FHyperactivity Disorder","Cardiovascular Abnormalities in Children With Attention-deficit\u002FHyperactivity Disorder Attending Assiut University Children Hospital: A Case Control Study","Inclusion Criteria:\n\nCase group :\n\n* Age is \\> 6 years and \\\u003C18 years old\n* Both sex\n* Patients diagnosed as having ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.\n* Currently receiving pharmacological treatment for at least six months\n\nControl group:\n\nHealthy, typically developing children , matched by age and sex to the case group\n\n\\-\n\nExclusion Criteria:\n\n* Age \\> 18 years\n* Patients who have a history of chronic diseases.\n* Patients with established hereditary syndromes or chromosomal abnormalities as Down syndrome.",{"count":134,"type":22},100,"OBSERVATIONAL","To identify the prevalence and types of cardiovascular abnormalities in children diagnosed with ADHD",[29],[139],"cardiovascular abnormalities","2026-06-13",{"date":142,"type":34},"2026-06-18",{"date":144,"type":22},"2026-06-15",{"date":146,"type":22},"2028-04-15",{"name":148,"class":41},"Assiut University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":42},"100422526","phase-4-multimodal-brain-imaging-of-the-neural-effects-of-methylphenidate-in-patients-with-adhd-100422526","NCT04781972","Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD","Inclusion Criteria:\n\n* right handed\n\nExclusion Criteria:\n\n* pregnant or breast feeding\n* past or current neurological disorder\n* non-ADHD cause of cognitive impairment\n* uncontrolled medical disorder\n* head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma\n* having an adverse reaction to methylphenidate, or other stimulant medication\n* having a contraindication to MRI\n* current smoking","40 Years",{"count":157,"type":22},30,[25],"The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit\u002Fhyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.",[29],"2025-10-15",{"date":163,"type":34},"2025-10-16",{"date":165,"type":34},"2021-07-27",{"date":167,"type":22},"2029-04-30",{"name":169,"class":41},"Johns Hopkins University",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":190,"locationsCount":42},"100539080","a-therapist-guided-internet-delivered-treatment-for-adults-with-adhd-attention-deficit--hyperactivity-disorder---an-open-effectiveness-trial-in-routine-care-100539080","NCT06299189","A Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit \u002F Hyperactivity Disorder) - an Open Effectiveness Trial in Routine Care","A Therapist Guided Internet-delivered Treatment for Adults With ADHD - an Open Effectiveness Trial in Routine Care","MinADHD","Inclusion criteria: \\|\n\n* Age ≥18\n* A self-reported diagnosis of ADHD\n* Access to and ability to use a computer, smartphone and the Internet.\n* Speaks, writes and reads Norwegian\n\nExclusion criteria:\n\n* In need of other psychological treatment for mental health illness such as borderline or personality disorder, bipolar disorder, substance abuse or psychosis.\n* Ongoing psychological treatment for ADHD or other psychiatric illnesses.",{"count":179,"type":22},200,[181],"NA","The primary objective of this study is to explore and evaluate the use and utility of a guided Internet-delivered psychological treatment for adults with ADHD with a combined focus on:\n\ni) Evaluating the impact of potential predictors to treatment adherence, treatment response, treatment use and utilty. ii) Evaluating the feasibility, clinical benefits and implementation process of the treatment in routine outpatient care. iii) Evaluate the cost-effectiveness of the treatment program.",[60,29,112,113],"2025-08-25",{"date":186,"type":34},"2025-08-26",{"date":188,"type":34},"2024-01-01",{"date":122,"type":22},{"name":191,"class":41},"Haukeland University Hospital",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":51,"sex":17,"minAge":199,"maxAge":95,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":215},"100555506","neurotrainer-cognitive-training-for-academic-focus-100555506","NCT06512974","NeuroTrainer Cognitive Training For Academic Focus","A Feasibility and Efficacy Study of NeuroTrainer Cognitive Training in Students With and Without Attention-Related Difficulties","Inclusion Criteria:\n\n* Diagnostic criteria met ADHD for any ADHD presentation type, with severity ratings of subthreshold, moderate or severe\n* Estimated IQ of 80 or greater\n* Between 11-17 years of age\n\nExclusion Criteria:\n\n* Presence of suicidality\n* Presence of psychotic disorders\n* Visual or hearing impairment\n* Presence of severe depression","11 Years",{"count":201,"type":22},155,[181],"This clinical trial aims to evaluate the feasibility and efficacy of NeuroTrainer cognitive training in improving attentional and executive control functions in students with and without attention-related difficulties.",[29,112,113],"2025-06-16",{"date":207,"type":34},"2025-06-19",{"date":209,"type":34},"2024-09-01",{"date":211,"type":22},"2026-02-28",{"name":213,"class":214},"NeuroTrainer","INDUSTRY",3,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":51,"sex":17,"minAge":53,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":228,"conditions":229,"keywords":236,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100534157","early-phase-1-psychoneuromentalism-disorder-a-medical-condition-that-affects-people-with-psychological-impairments-from-health-issues-100534157","NCT06235177","Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues","Psychoneuromentalism Disorder: A Condition Resulting From Behavioral Impairments, Neurodiversity, and Neurobehavioral Dysfunctions Related to the Mental and Emotional State of a Person","PNMD","Inclusion Criteria:\n\n* Clinical Diagnosis of anxiety, schizoaffective disorder, bipolar disorder, ADHD, Dementia, or other psychological issues and disorders; autoimmune disease such as fibromyalgia, lupus, and thyroid disease, neuropathy and chronic fatigue syndrome\n* Must be able to swallow tablets\n\nExclusion Criteria:\n\n* Children under the age of 18\n* Must not be on any blood thinner medications\n* Chronically ill patients","80 Years",{"count":157,"type":22},[227],"EARLY_PHASE1","Psychoneuromentalism Disorder is a disorder arising in the mind; that is related to the mental and emotional state of a person. It is the science of mental life. The body has a natural design to heal itself. This is a mental phenomena that cannot be explained, until now.\n\nPsychoneuromentalism Disorder is a new condition resulting from behavioral impairments, neurodiversity, and neurobehavioral dysfunctions that are related to the mental and emotional state of a participant.",[230,231,29,232,233,234,114,235],"Schizoaffective Disorder, Bipolar Type","Bipolar Disorder","Dissociative Disorder","Stress Disorder","Dementia","Chronic Fatigue Syndrome",[237,238,239,240,241,114,242,60,243],"Psychology","Neuroscience","Mental Health","Disorder","Stress","Psychoneuromentalism Disorder","Fatigue","2024-08-09",{"date":246,"type":34},"2024-08-12",{"date":248,"type":22},"2024-10-10",{"date":250,"type":22},"2025-09-19",{"name":252,"class":41},"The Essence of Integrative Health and Medicine Practice"]